Numerous investment firms have been altering their stakes in bio-tech company
Leidos Holdings (LDOS). Transactions include acquisitions and divestments from entities such as Dynamic Advisor Solutions, Envestnet, SG Americas, and Ritholtz Wealth Management among others. Leidos has been capitalizing on opportunities in the defense sector, winning a major
$35M contract for adapting Pentagon's confidential data networks, and securing modern data sharing across the Department of Defense mission networks. Brokerages have set an average
price target for LDOS at around $176.46, indicating a potential upside. Leidos' positive growth potentials were reflected in its Q1 2025 earnings call. Meanwhile, the company outperformed the market year-to-date, further attracting investors attention. Some underperformance and stock devaluation was observed, partly offset by promising deals like the
$205 Million contract and the AI-powered security partnership for critical government systems protection. A quarterly cash dividend of $0.40 is also set to be delivered, reiterating the firm's goodwill to shareholders.
Leidos Holdings LDOS News Analytics from Mon, 23 Dec 2024 08:00:00 GMT to Sat, 21 Jun 2025 17:51:50 GMT -
Rating 6
- Innovation 0
- Information 7
- Rumor 3
